Evidence map›Paper›PMID 26573914›Full record

ReviewClinical reviews in allergy & immunology2016

A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts.

Mary Beth Humphrey, Mary C Nakamura

Abstract readReview
In one paragraph

Review in Clinical reviews in allergy & immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 92 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mary Beth HumphreyDivision of Rheumatology, Immunology, and Allergy, Department of Medicine, University of Oklahoma Health Sciences Center, 975 NE 10th St., BRC209, Oklahoma City, OK, 73104, USA.
Mary C NakamuraDivision of Rheumatology, Department of Medicine, University of California, San Francisco, CA, USA. mary.nakamura@ucsf.edu.
University of California, San Francisco · USUniversity of Oklahoma Health Sciences Center · US

Funding

Calcium Regulation in OsteoclastsR01AR064211 · NIAMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HUMPHREY, MARY BETH, TSIOKAS, LEONIDAS · 2013 to 2017
$2.1M
DAP-12 ASSOCIATED RECEPTORS IN OSTEOCLASTSR01AR050038 · NIAMS · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI NAKAMURA, MARY C · 2004 to 2008
$1.5M
Mechanism of ITAM Signal Regulation in OsteoclastsR01DE019398 · NIDCR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HUMPHREY, MARY BETH · 2008 to 2012
$1.3M
Effects of Aging on Macrophages and Bone RegenerationR01AG046282 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARCUCIO, RALPH S, NAKAMURA, MARY C · 2013 to 2016
$784k
NIAMS NIH HHS R01 AR050038NIAMS NIH HHS R01 AR064211NIA NIH HHS R01 AG046282NIDCR NIH HHS R01 DE019398
6 · The paper itself

Abstract

Osteoclasts require coordinated co-stimulation by several signaling pathways to initiate and regulate their cellular differentiation. Receptor activator for NF-κB ligand (RANKL or TNFSF11), a tumor necrosis factor (TNF) superfamily member, is the master cytokine required for osteoclastogenesis with essential co-stimulatory signals mediated by immunoreceptor tyrosine-based activation motif (ITAM)-signaling adaptors, DNAX-associated protein 12 kDa size (DAP12) and FcεRI gamma chain (FcRγ). The ITAM-signaling adaptors do not have an extracellular ligand-binding domain and, therefore, must pair with ligand-binding immunoreceptors to interact with their extracellular environment. DAP12 pairs with a number of different immunoreceptors including triggering receptor expressed on myeloid cells 2 (TREM2), myeloid DAP12-associated lectin (MDL-1), and sialic acid-binding immunoglobulin-type lectin 15 (Siglec-15); while FcRγ pairs with a different set of receptors including osteoclast-specific activating receptor (OSCAR), paired immunoglobulin receptor A (PIR-A), and Fc receptors. The ligands for many of these receptors in the bone microenvironment remain unknown. Here, we will review immunoreceptors known to pair with either DAP12 or FcRγ that have been shown to regulate osteoclastogenesis. Co-stimulation and the effects of ITAM-signaling have turned out to be complex, and now include paradoxical findings that ITAM-signaling adaptor-associated receptors can inhibit osteoclastogenesis and immunoreceptor tyrosine-based inhibitory motif (ITIM) receptors can promote osteoclastogenesis. Thus, co-stimulation of osteoclastogenesis continues to reveal additional complexities that are important in the regulatory mechanisms that seek to maintain bone homeostasis.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsBiomarkersBone ResorptionHumansImmunomodulationOsteoclastsProtein BindingProtein Interaction Domains and MotifsRANK LigandReceptor Activator of Nuclear Factor-kappa BReceptors, FcReceptors, ImmunologicSignal TransductionAdaptor Proteins, Signal TransducingBiomarkersRANK LigandReceptor Activator of Nuclear Factor-kappa BReceptors, FcReceptors, ImmunologicFc receptorImmunoreceptorITAMOsteoclastOsteoimmunologyRANK

Identifiers

PMID26573914
PMCPMC4867136
OpenAlexW2178747516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.